Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18441075 | 0.99 | MTNR1A (0.57) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL25079811 | 0.92 | HTR2C (0.58) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL6358819 | 0.92 | HTR2C (0.58) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL25079814 | 0.92 | HTR2C (0.58) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL18474137 | 0.85 | MTNR1A (0.65) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL2264043 | 0.84 | HTR2C (0.60) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL11847902 | 0.83 | HTR2C (0.59) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL2781869 | 0.80 | SLC6A4 (0.56) | HTR2AHTR2CHTR2BHTR1ASLC6A4 | |
| SCHEMBL2783286 | 0.80 | SLC6A4 (0.54) | HTR2AHTR2CIDO1HTR1ASLC6A4 | |
| SCHEMBL3546634 | 0.80 | CYP1A2 (0.58) | MTNR1AMTNR1BHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017023894-A1 | MTHFD2 INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MTNR1A 1886/4885MTNR1B 766/4885HTR2A 1004/4885 |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | MTNR1A 2502/4885MTNR1B 1005/4885HTR2A 1384/4885 |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | OPRL1, OPRM1, OGFRL1 | MTNR1A 253/4885MTNR1B 304/4885HTR2A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.